Researchers have identified a potential new strategy for treating fragile X syndrome -- the most common inherited cause of intellectual disability. They have found that a class of drugs called phosphoinositide-3 kinase inhibitors can correct defects in the anatomy of neurons seen in a mouse model of fragile X syndrome. In experiments with cultured neurons from the hippocampus, a brain region involved in learning and memory, the drugs could restore normal appearance and levels of protein production at synapses.